Short answer: With 2 mL of bacteriostatic water in a BPC-157 + TB-500, 5 mg + 5 mg vial (5 mg BPC-157 + 5 mg TB-500), every 10 units on a U-100 insulin syringe holds 250 mcg BPC-157 and 250 mcg TB-500. The ratio is fixed, so you cannot change one peptide without changing the others. Amounts are arithmetic on the label, not dose advice.
The "Wolverine" name is used for BPC-157 and TB-500 together. Sometimes that means one vial with both peptides already mixed (a blend), and sometimes two separate vials sold as a kit (a stack). This page is the math for the single-vial blend. With two separate vials, each one is ordinary single-peptide math.
Single-vial versions are commonly labeled 5 mg + 5 mg (10 mg total) or 10 mg + 10 mg (20 mg total). Both are 1:1, so each draw holds equal amounts of the two.
| Peptide | Commonly labeled | Share of vial | Guide |
|---|---|---|---|
| BPC-157 | 5 mg | 50% | BPC-157 guide |
| TB-500 | 5 mg | 50% | TB-500 guide |
| Peptide | Commonly labeled | Share of vial | Guide |
|---|---|---|---|
| BPC-157 | 10 mg | 50% | BPC-157 guide |
| TB-500 | 10 mg | 50% | TB-500 guide |
The water volume changes how big each draw is, not what is in the vial. The highlighted row is 2 mL.
| Water added | Units in vial | BPC-157 / 10 units | TB-500 / 10 units |
|---|---|---|---|
| 2 mL | 200 | 250 mcg | 250 mcg |
| 3 mL | 300 | 166.7 mcg | 166.7 mcg |
| 5 mL | 500 | 100 mcg | 100 mcg |
| Water added | Units in vial | BPC-157 / 10 units | TB-500 / 10 units |
|---|---|---|---|
| 2 mL | 200 | 500 mcg | 500 mcg |
| 3 mL | 300 | 333.3 mcg | 333.3 mcg |
| 5 mL | 500 | 200 mcg | 200 mcg |
| Units drawn | Volume | BPC-157 | TB-500 |
|---|---|---|---|
| 5 units | 0.05 mL | 125 mcg | 125 mcg |
| 10 units | 0.1 mL | 250 mcg | 250 mcg |
| 20 units | 0.2 mL | 500 mcg | 500 mcg |
| 30 units | 0.3 mL | 750 mcg | 750 mcg |
For any other vial, water volume or draw, the free peptide blend calculator does the same math for 2 to 5 peptides.
mg of that peptide ÷ mL of water. For BPC-157 + TB-500, 5 mg + 5 mg with 2 mL: BPC-157 5 ÷ 2 = 2.5 mg/mL, TB-500 5 ÷ 2 = 2.5 mg/mL.amount ÷ its concentration = mL. Example: 250 mcg of TB-500 is 0.25 ÷ 2.5 = 0.1 mL.mL × 100 on a U-100 syringe: 0.1 × 100 = 10 units.mL × concentration for each other peptide: 250 mcg BPC-157.A blend is one solution, so every draw takes the same share of each peptide. In the example above, drawing 10 units for 250 mcg of TB-500 also gives 250 mcg BPC-157. Doubling the draw to 20 units doubles all of them, to 500 mcg BPC-157. There is no draw that changes one peptide and leaves the others where they are.
More or less water does not help either: it changes how many units each draw is, not the ratio between the peptides. If you need to set the amount of each peptide on its own, they have to be in separate vials (a stack), each with its own single-peptide calculation.
We found no published human study of Wolverine blend as a blend. Below is what is published for each peptide on its own. "Amounts studied" are what a study gave or reported, often by a different route; they are not personalized advice. Confirm anything about your own use with your prescriber.
Not FDA approved. Research is mostly in animals: a 2025 systematic review found 36 studies, 35 of them preclinical. A 2026 systematic review found three small human studies (30 people in total), none with a control group, and rated the certainty of the evidence very low. [1][2][3]
Amounts studied: The only published human amounts come from small uncontrolled reports. One intravenous safety pilot gave 10 mg and then 20 mg infusions to 2 adults. No controlled trial has studied BPC-157 injected under the skin.
Not FDA approved. TB-500 is a synthetic copy of a short active region of thymosin beta-4 (N-acetylated LKKTETQ). There are no published human studies of TB-500 itself; research on it is in cells and animals. [4][5]
Amounts studied: None published for TB-500. The only human dosing data are for full-length recombinant thymosin beta-4, a larger and different molecule, given into a vein at 0.05 to 25 mcg/kg in a phase I safety study.
Regulatory status. As of October 2026 none of the peptides in these blends is FDA approved. In July 2026 an FDA advisory committee voted 8 to 6 to recommend adding BPC-157, KPV and TB-500 to the list of substances pharmacies may compound. FDA staff had recommended against it, the vote is not binding, and none has been added yet. [6]
Blend compositions were checked against several retail product listings in October 2026. We do not name or link sellers.